Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03320252 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Endurant CHevAr New Indication Trial: ENCHANT

Study acronym: ENCHANT
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Mar 2026 to Apr 22, 2026v48
  2. 3 versions Re-verified since May 15, 2025, no change to tracked fieldsv45-v47
  3. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 29 to 26
    v44
  4. Site details revised at 2 of 29 sitesv43
  5. Site details revised at 2 of 29 sitesv42
Show 40 earlier versionsHide 40 earlier versions
  1. Site details revised at 1 of 29 sitesv41
  2. Site contacts updated at 1 of 29 sitesv40
  3. Site details revised at 1 of 29 sitesv39
  4. Primary completion date: May 2025 to Mar 2026
    • Study completion date: Nov 2029 to Jul 2030
    v38
  5. Site contacts updated at 1 of 29 sitesv37
  6. Site details revised at 1 of 29 sitesv36
  7. Primary completion date: Apr 2025 to May 2025
    • Study completion date: Apr 2029 to Nov 2029
    • Site details revised at 2 of 29 sites
    v35
  8. Primary completion date: May 12, 2024 to Apr 2025
    • Study completion date: May 12, 2028 to Apr 2029
    v34
  9. Site details revised at 1 of 29 sitesv33
  10. Site details revised at 1 of 29 sitesv32
  11. Site details revised at 1 of 29 sitesv31
  12. Site contacts updated at 1 of 29 sitesv30
  13. Site details revised at 1 of 29 sitesv29
  14. Primary completion date: Jul 31, 2023 to May 12, 2024
    • Study completion date: Dec 31, 2027 to May 12, 2028
    • Site details revised at 1 of 29 sites
    v28
  15. Site details revised at 2 of 29 sitesv27
  16. Site details revised at 2 of 29 sitesv26
  17. Lead sponsor: Medtronic Endovascular to Medtronic Cardiovascular
    • Site details revised at 1 of 29 sites
    v25
  18. Primary endpoints: 3 to 2v24 Show 4 more changesShow less
    • Study completion date: Dec 31, 2025 to Dec 31, 2027
    • Eligibility criteria expanded, about 62 words
    • Secondary endpoints: 2 to 4
    • Site details revised at 1 of 29 sites
  19. Study sites: 28 to 29v23
  20. Study sites: 26 to 28v22
  21. Site details revised at 2 of 26 sitesv21
  22. Study sites: 25 to 26v20
  23. Site details revised at 1 of 25 sitesv19
  24. Site details revised at 5 of 25 sitesv18
  25. Trial status: Active, Not Recruiting to Recruiting
    • Primary completion date: Dec 1, 2022 to Jul 31, 2023
    • Study completion date: Dec 1, 2024 to Dec 31, 2025
    • Site details revised at 25 of 25 sites
    v17
  26. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 25 of 25 sites
    v16
  27. Re-verified, no change to tracked fieldsv15
  28. Primary completion date: Mar 1, 2020 to Dec 1, 2022
    • Study completion date: Mar 1, 2023 to Dec 1, 2024
    v14
  29. Study sites: 26 to 25v13
  30. Re-verified, no change to tracked fieldsv12
  31. Site details revised at 1 of 26 sitesv11
  32. Re-verified, no change to tracked fieldsv10
  33. Site details revised at 8 of 26 sitesv9
  34. Study sites revised (26)v8
  35. Site details revised at 3 of 26 sitesv7
  36. Study sites: 5 to 26v6
  37. Re-verified, no change to tracked fieldsv5
  38. Study sites: 2 to 5v4
  39. Start date changed from estimate of Oct 30, 2017 to Oct 26, 2017v3
  40. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the post-market study is to assess the clinical outcomes, safety, and performance of the Endurant Chimney Graft Technique (Endurant Stent Graft Systems used with a balloon-expandable covered stent graft) for treatment of juxtarenal aortic aneurysms with a short infrarenal neck in a real world setting.
Trial Details
NCT Number NCT03320252
Lead Sponsor Medtronic Cardiovascular
Conditions
(from sponsor)		 AAA - Abdominal Aortic Aneurysm
Related terms Aortic Aneurysm, Abdominal
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov